Calendrier des promotions Clearside Biomedical, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. plus de détailsParamètres de base
IPO date
2016-06-02
ISIN
US1850631045
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 42.14 | 1 |
| P/BV | -1.8 | 0 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -116.16 | 0 |
| ROE | 125.45 | 10 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0289 | 10 |
| Debt/Ratio | 0.028 | 10 |
| Debt/Equity | -1.65 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | -78.94 | 0 |
| Rentabilité Ebitda, % | 36.02 | 5 |
| Rentabilité EPS, % | 20.05 | 4 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 0.8197 $ | 0 $ | 0 $ | -4.39 % | 0 % | 0 % |
| common.calendar.number_days.7d | 0.8441 $ | 0 $ | 0 $ | -7.16 % | 0 % | 0 % |
| common.calendar.number_days.30d | 0.833 $ | 0.7837 $ | 0.8998 $ | -5.92 % | 0 % | 0 % |
| common.calendar.number_days.90d | 0.9 $ | 0.7491 $ | 1.03 $ | -12.92 % | 0 % | 0 % |
| common.calendar.number_days.180d | 1.07 $ | 0.7491 $ | 1.13 $ | -26.76 % | 0 % | 0 % |
| common.calendar.number_days.1y | 1.39 $ | 0.7491 $ | 1.58 $ | -43.62 % | 0 % | 0 % |
| common.calendar.number_days.3y | 1.31 $ | 0.68 $ | 2.02 $ | -40.18 % | 0 % | 0 % |
| common.calendar.number_days.5y | 1.93 $ | 0.68 $ | 7.2 $ | -59.39 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0 $ | 0.5858 $ | 24.72 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 0.8723 $ | 0.7491 $ | 1.13 $ | -10.16 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | President, CEO & Director | 836.15k | 1952 (73 année) |
| Mr. Charles A. Deignan | Chief Financial Officer | 568.68k | 1964 (61 année) |
| Ms. Jenny R. Kobin | Head of Investor Relations | N/A | 1967 (58 années) |
| Mr. Rick McElheny | Senior Vice President of Corporate Development & Alliance Management | N/A | |
| Mr. Rafael V. Andino | Senior Vice President of Engineering & Manufacturing | N/A | 1965 (60 années) |
| Ms. Susan L. Coultas Ph.D. | Chief Clinical Officer | N/A | |
| Mr. Leslie B. Zacks | Secretary | N/A | 1969 (56 années) |
| Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. | Chief Medical Officer |
Informations sur l'entreprise
Adresse: United States, Alpharetta. GA, 900 North Point Parkway - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://clearsidebio.com
Site web: https://clearsidebio.com
